公开(公告)号：US20240390264A1

公开(公告)日：2024-11-28

申请号：US18794030

申请日：2024-08-05

Applicant: Albert Einstein College of Medicine

Inventor： Joel M. Friedman

IPC: A61K9/00 ,  A61K9/06 ,  A61K31/05 ,  A61K31/12 ,  A61K31/121 ,  A61K31/352 ,  A61K31/366 ,  A61K31/4375 ,  A61K31/593 ,  A61K47/10 ,  A61K47/12 ,  A61P7/00 ,  A61P37/06

Abstract: A transdermal formulation for the delivery of one or more active agents to a subject is provided. The formulation can be applied to the treatment of various diseases or conditions associated with an elevated CD38 level.

公开(公告)号：US20240374734A1

公开(公告)日：2024-11-14

申请号：US18690040

申请日：2022-09-07

Applicant: Integrated Nanotherapeutics Inc.

Inventor： Sam Chen ,  Anne Nguyen ,  Joshua Zaifman

IPC: A61K47/54 ,  A61K9/127 ,  A61K9/51 ,  A61K31/573 ,  A61K39/00 ,  A61K47/69 ,  A61P37/06

Abstract: An immunomodulatory combination including: (i) a lipid conjugate comprising an immunomodulatory agent covalently linked to a lipophilic moiety by a cleavable linkage or through a cleavable linker, and (ii) an antigen and/or one or more nucleic acids that encode the antigen. The antigen is a protein, polypeptide, peptide, lipoprotein, glycolipid, polynucleotide, or polysaccharide. The lipid conjugate and the antigen and/or the one or more nucleic acids that encode the antigen are formulated in separate delivery vehicles or co-formulated in the same delivery vehicle.

公开(公告)号：US12139532B2

公开(公告)日：2024-11-12

申请号：US15489254

申请日：2017-04-17

Applicant: ImmuNext, Inc. ,  THE TRUSTEES OF DARTMOUTH COLLEGE

Inventor： Jay Rothstein ,  Isabelle Lemercier ,  Linda Snyder ,  Gordon Powers

IPC: C07K16/28 ,  A61K38/17 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P1/00 ,  A61P1/16 ,  A61P13/12 ,  A61P17/06 ,  A61P19/02 ,  A61P37/06

Abstract: The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.

公开(公告)号：US20240366594A1

公开(公告)日：2024-11-07

申请号：US18563774

申请日：2022-05-27

Applicant: The Brigham and Women's Hospital, Inc. ,  The General Hospital Corporation ,  The Children`s Medical Center Corporation

Inventor： Jeffrey M. Karp ,  Ivan Zanoni ,  Pui Yan Ma ,  Ralph Mazitschek ,  Stephen J. Haggarty

IPC: A61K31/505 ,  A61K31/4406 ,  A61K45/06 ,  A61P11/00 ,  A61P37/06 ,  C12Q1/6883 ,  G01N33/68

Abstract: Described herein are compositions and methods that inhibit class I and IIb HIDACs for use in inhibiting NETosis and conditions associated with NETosis.

公开(公告)号：US12129294B2

公开(公告)日：2024-10-29

申请号：US18105316

申请日：2023-02-03

Applicant: AbbVie Inc.

Inventor： Gregg Timony ,  Sheila Gujrathi ,  Robert Peach ,  Allan Olson

IPC: C07K16/24 ,  A61K31/436 ,  A61K31/519 ,  A61K31/58 ,  A61K38/13 ,  A61K39/395 ,  A61K45/06 ,  A61P1/00 ,  A61P37/06

CPC classification number: C07K16/244 ,  A61K31/436 ,  A61K31/519 ,  A61K31/58 ,  A61K38/13 ,  A61K39/3955 ,  A61K45/06 ,  A61P1/00 ,  A61P37/06 ,  C07K2317/56

Abstract: The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an interleukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.

公开(公告)号：US20240355416A1

公开(公告)日：2024-10-24

申请号：US18753994

申请日：2024-06-25

Applicant: Scipher Medicine Corporation

Inventor： Susan GHIASSIAN ,  Theodore R. MELLORS ,  Marc SANTOLINI ,  Asher AMELI ,  Nancy SCHOENBRUNNER ,  Viatcheslav R. AKMAEV ,  Keith J. JOHNSON

IPC: G16B20/20 ,  A61K38/17 ,  A61P19/02 ,  A61P37/06 ,  C07K16/24 ,  G16B40/00 ,  G16H10/60 ,  G16H20/10 ,  G16H50/20 ,  G16H50/70

CPC classification number: G16B20/20 ,  A61K38/1793 ,  A61P19/02 ,  A61P37/06 ,  C07K16/241 ,  G16B40/00 ,  G16H10/60 ,  G16H20/10 ,  G16H50/20 ,  G16H50/70 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/76

Abstract: Presented herein are systems and methods for developing classifiers useful for predicting response to particular treatments. For example, in some embodiments, the present disclosure provides a method of treating subjects suffering from an autoimmune disorder, the method comprising administering an alternative to anti-TNF therapy to subjects who have been determined to be non-responsive via a classifier established to distinguish between responsive and non-responsive prior subjects in a cohort who have received the anti-TNF therapy.

公开(公告)号：US12122814B2

公开(公告)日：2024-10-22

申请号：US18501584

申请日：2023-11-03

Applicant: DEKA BIOSCIENCES, INC.

Inventor： John Mumm

IPC: C07K14/54 ,  A61K38/00 ,  A61K39/395 ,  A61P35/00 ,  A61P37/06 ,  C07K14/55 ,  C07K16/10 ,  C07K16/28 ,  C07K16/32 ,  C07K16/46 ,  A61K39/00

CPC classification number: C07K14/5428 ,  A61P35/00 ,  A61P37/06 ,  C07K14/5406 ,  C07K14/55 ,  C07K16/10 ,  C07K16/1045 ,  C07K16/2803 ,  C07K16/2863 ,  C07K16/2896 ,  C07K16/32 ,  C07K16/464 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2319/30

Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.

公开(公告)号：US12116392B2

公开(公告)日：2024-10-15

申请号：US18501884

申请日：2023-11-03

Applicant: DEKA BIOSCIENCES, INC.

Inventor： John Mumm

IPC: C07K14/54 ,  A61K38/00 ,  A61K39/395 ,  A61P35/00 ,  A61P37/06 ,  C07K14/55 ,  C07K16/10 ,  C07K16/28 ,  C07K16/32 ,  C07K16/46 ,  A61K39/00

CPC classification number: C07K14/5428 ,  A61P35/00 ,  A61P37/06 ,  C07K14/5406 ,  C07K14/55 ,  C07K16/10 ,  C07K16/1045 ,  C07K16/2803 ,  C07K16/2863 ,  C07K16/2896 ,  C07K16/32 ,  C07K16/464 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2319/30

Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.

公开(公告)号：US20240336699A1

公开(公告)日：2024-10-10

申请号：US18750233

申请日：2024-06-21

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Sonny Oon ANG ,  Enli LIU ,  Elizabeth SHPALL ,  Katy REZVANI

IPC: C07K16/28 ,  A61K35/17 ,  A61K38/00 ,  A61K39/00 ,  A61P37/06 ,  C07K14/54 ,  C07K14/705 ,  C07K14/71 ,  C07K14/725 ,  C12N15/52 ,  C12N15/86

CPC classification number: C07K16/2896 ,  A61K35/17 ,  A61P37/06 ,  C07K14/5443 ,  C07K14/70503 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/71 ,  C07K16/2803 ,  C07K16/2863 ,  C12N15/52 ,  C12N15/86 ,  A61K38/00 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33

Abstract: Provided herein are chimeric antigen receptors (CARs) comprising a truncated EGFRvIII (Ev3) in the hinge region of the CAR and/or a humanized scFv. Further provided herein are immune cells expressing the CARs as well as methods of their use in the treatment of immune disorders.

公开(公告)号：US20240336665A1

公开(公告)日：2024-10-10

申请号：US18708113

申请日：2022-11-07

Applicant: Acroimmune Guangzhou Biotech Ltd

Inventor： Qunmin ZHOU ,  Xianfeng FANG ,  Dongling LI ,  Libing MU

IPC: C07K14/47 ,  A61K38/00 ,  A61P37/06

CPC classification number: C07K14/4727 ,  A61P37/06 ,  A61K38/00 ,  C07K2319/30

Abstract: Provided are compositions of proteins based on fusion of one or more copy of the core peptide to the Fc fragment of human immunoglobulin and their use in treating diseases propagated by inflammations associated with tissue injuries.